Global /United States /Healthcare /Drug Manufacturers - General /RGEN
chevron_leftBack
Repligen Corp. logo

Repligen Corp.

RGEN
NASDAQ: RGEN Delayed
113.11USD -3.7%
As of 7 June 2026, Repligen Corp. has a market cap of $6.38B USD, ranking #3139 globally and #947 in the United States. It ranks #233 in the Healthcare sector, and #89 in the Drug Manufacturers - General industry.
Global Rank
3139
Country Rank
947
Sector Rank
233
Industry Rank
89
Key Stats
Market Cap
$6.38BUSD
Enterprise Value
$6.25BUSD
Revenue (TTM)
$738.26MUSD
EBITDA (TTM)
$124.44MUSD
Net Income (TTM)
$48.89MUSD
EBITDA Margin
17%
Profit Margin
6.6%
PE Ratio
131.5
Forward PE
57.5
PS Ratio
8.6
PB Ratio
3.1
EV/EBITDA
50.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Olivier Loeillot open_in_new
Employees
2,000
Founded
1981
Website
repligen.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-3.7% -16% 0.8% -31% -27% -23%

News

Loading...

RGEN Analyst Forecasts

Loading...

Markets

Exchange Ticker Price
NASDAQ
MIC: XNAS
PRIMARY
RGEN
Repligen Corp
ISIN: US7599161095
Shares Out.:
56.408M1 Shares Float: 53.357M2
TV:
SA:
YF:
GF:
NQ:
BA:
MS:
113.11 USD
Borsa Italiana
MIC: XMIL
1RGEN
Repligen Corp
ISIN: US7599161095
TV:
SA:
YF:
GF:
BA:
MS:
106.40 EUR
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Repligen Corp.

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company’s products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Similar Companies

Industry: Drug Manufacturers - General (United States)
Name
Market Cap diff.
PE
LLY
$761.68B
12K%
38.1
JNJ
$547.28B
8K%
26.4
ABBV
$360.63B
6K%
97.4
MRK
$274.03B
4K%
15.1
PFE
$149.38B
2K%
19.5
$117.58B
2K%
16.8
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
$324.68B
256.25B CHF
5K%
19.9
AZN
$289.43B
215.59B GBP
4K%
27.6
NOVN
$277.35B
218.9B CHF
4K%
20.5
NOVO-B
$182.72B
1.18T DKK
3K%
11.5
SAN
$110.65B
95.26B EUR
2K%
19.9
GSK
$108.68B
80.96B GBP
2K%
14.6
chevron_leftBack